SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC...
-
Upload
candace-woods -
Category
Documents
-
view
212 -
download
0
description
Transcript of SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC...
![Page 1: SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell…](https://reader037.fdocuments.in/reader037/viewer/2022090107/5a4d1c117f8b9ab0599f6fe0/html5/thumbnails/1.jpg)
SNU423 SK-Hep1 HepG2 HA22T
AR
GAPDH
Supplemental Fig. S1 Endogenous AR expression in various HCC cell lines
Supplemental Fig. S2 Multiple E:T ratio for NK cells against HCC cells
![Page 2: SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell…](https://reader037.fdocuments.in/reader037/viewer/2022090107/5a4d1c117f8b9ab0599f6fe0/html5/thumbnails/2.jpg)
Supplemental Fig. S3 Tunel assay for NK cells against SNU-423 cells
SNU423-Scr SNU423-shAR0
5
10
15**
Apop
tosi
s ra
te (f
old
incr
ease
)
SNU423-Scr SNU423-shAR
0 2 6 12 240
100
200
300
400
SK-pBABESK-AR3SK-AR7SNU423-ScrSNU423-shAR
*NS
*
*NS
**
***
*** ***
hours
IL-1
2 p3
5 (p
g/m
l)
Supplemental Fig. S4 IL-12p35 release of HCC cells with various AR
Supplemental Fig. S5 MAGNET V2.0 calculated correlation between IL12A and AR
![Page 3: SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell…](https://reader037.fdocuments.in/reader037/viewer/2022090107/5a4d1c117f8b9ab0599f6fe0/html5/thumbnails/3.jpg)
Nontumor Peritumor Intratumor
Patient 22CD56
Supplemental Fig. S6 Distribution of NK cells in different region of HCC
Nontumor Paritumor Intratumor0
20
40
60 *
***
CD
56+
cells
per
fiel
d
SK-pBabe SK-AR70
20
40
60
80
100
120
-++++++
Spearman R= -0.329P value= 0.1165
n=12 n=12
Perc
enta
ge %
Vehicle Sorafenib0
20
40
60
80
100
120
-++++++
n=6 n=6 IL-12A
Perc
enta
ge %
Supplemental Fig. S9 Correlation analysis for animal tumor samples staining
0 4 6 80
100
200
300
400 **
*SK-Hep1
+sorafenib (umol/L)
IL-1
2 p3
5 (p
g/m
l)
Supplemental Fig. S7 IL-12p35 release induced by sorafenib treatment
0 4 6 80
100
200
300
400 ***
*SNU-423
+sorafenib (umol/L)
IL-1
2 p3
5 (p
g/m
l)
Supplemental Fig. S8 Ectopic AR in HCC cells interrupted sorafenib induced IL-12A
![Page 4: SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell…](https://reader037.fdocuments.in/reader037/viewer/2022090107/5a4d1c117f8b9ab0599f6fe0/html5/thumbnails/4.jpg)
Supplemental figure 1. Different expression level of AR in HCC cells lines we applied. Supplemental figure 2. LDH cytotoxic assay performed with HA22T-AR (upper panel) or SK-AR (lower panel) cells. Multiple E:T ratios were compared. Data shown are mean±SEM. *** P< 0.001, ** P<0.01, * P<0.05.
Supplemental figure 3. TUNEL staining for second HCC cell line, SNU423, after adding NK-92MI cells. Left panel is representative TUNEL staining image and right panel is quantification result. *** P< 0.001, ** P<0.01, * P<0.05. Supplemental figure 4. Culture media was collected from HCC cells with different AR expression at different time points. Then we detected IL-12p35 in media with an ELISA kit. *** P< 0.001, ** P<0.01, * P<0.05.
Supplemental figure 5. Correlation analysis result generated from MAGNET V2.0 website by using TCGA database.
Supplemental figure 6. Representative image for CD56+ NK cells in nontumor, peritumor and intratumor tissue, and CD56+ cells quantification. *** P< 0.001, ** P<0.01, * P<0.05.
Supplemental figure 7. Culture media was collected from HCC cells treated with sorafenib for 24 hours. Then we detected IL-12p35 in media with an ELISA kit. *** P< 0.001, ** P<0.01, * P<0.05.
Supplemental figure 8. Ectopic AR was provided into HCC cells by lentivirus, then treated with 4uM sorafenib for further testing IL-12A expression with Western Blot.
Supplemental figure 9. Quantification results for staining IL-12A and AR in orthotopic HCC tumors from nude mice. Left panel is comparing AR(+) and AR(-). Right panel is showing the difference after sorafenib treatment.